CytomX Therapeutics (CTMX) Net Margin (2014 - 2026)
CytomX Therapeutics (CTMX) reported Net Margin of 177.89% for Q1 2026, down 22409.0% on a YoY basis from N/an in Q1 2025, and up 95.55% quarter-over-quarter from 3998.49% in Q4 2025.
CytomX Therapeutics (CTMX) Net Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics has reported Net Margin for 13 years, with the latest figure at 177.89% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 22409.0% year-over-year to 177.89%; the trailing twelve-month figure through Mar 2026 stood at 166.4% (down 19459.0% YoY), and the FY2025 full-year result was 26.73%, down 4981.0% from the prior year.
- Net Margin for Q1 2026 stood at 177.89%, up from 3998.49% in the prior quarter.
- The five-year high for Net Margin was 49.55% in Q4 2024, with the low at 3998.49% in Q4 2025.
- Historically, Net Margin has averaged 305.13% across 5 years, with a median of 14.09% in 2023.
- Annual changes were most pronounced in 2023 — Net Margin jumped 33968 bps — and 2025, when it plunged 404804 bps.
- CytomX Therapeutics' Net Margin stood at 43.61% in 2022, then surged by 107 bps to 3.15% in 2023, then soared by 1475 bps to 49.55% in 2024, then plunged by 8169 bps to 3998.49% in 2025, then soared by 96 bps to 177.89% in 2026.
- The last three Net Margin figures came in at 177.89% (Q1 2026), 3998.49% (Q4 2025), and 238.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | -177.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.89% |
| Dec 31, 2025 | -3,998.49% |
| Sep 30, 2025 | -238.62% |
| Jun 30, 2025 | -0.83% |
| Mar 31, 2025 | 46.20% |
| Dec 31, 2024 | 49.55% |
| Sep 30, 2024 | 17.16% |
| Jun 30, 2024 | -26.02% |
| Mar 31, 2024 | 33.26% |
| Dec 31, 2023 | 3.15% |
| Sep 30, 2023 | 11.34% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |
| Jun 30, 2021 | -303.99% |